← Back to headlines
BMO Reiterates Incyte Stock Rating Following CMS Pricing Agreement
BMO has reaffirmed its rating on Incyte stock, pointing to the strategic implications of the recent CMS pricing agreement for the biopharmaceutical company's pipeline.
1 Sept, 14:00 — 1 Sept, 14:00
Sources
Showing 1 of 1 sources
